Overview

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

Status:
Completed

Trial end date:
2007-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Aztreonam